|
NCCN Pharmacy Updates: Establishing a Place in Therapy for Biosimilars in Oncology |
1.00 |
06/08/2020 - 12:00am to 01/10/2021 - 12:00am |
|
NCCN Pharmacy Updates: Emerging Strategies in the Treatment of Venous Thromboembolism |
1.00 |
06/08/2020 - 12:00am to 03/07/2021 - 12:00am |
|
NCCN Pharmacy Updates: Assessment and Management of CAR T-Cell Related Toxicities |
1.00 |
06/08/2020 - 12:00am to 11/01/2020 - 12:00am |
|
NCCN Guidelines® Insights - Uveal Melanoma, Version 1.2019 |
1.00 |
02/10/2020 - 12:00am to 02/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2020 |
1.00 |
08/10/2020 - 12:00am to 08/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Rectal Cancer, Version 6.2020 |
1.00 |
07/10/2020 - 12:00am to 07/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Primary Cutaneous Lymphomas, Version 2.2020 |
1.00 |
05/10/2020 - 12:00am to 05/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Ovarian Cancer, Version 1.2019 |
1.00 |
08/10/2019 - 12:00am to 08/10/2020 - 12:00am |
|
NCCN Guidelines® Insights - Non-Small Cell Lung Cancer, Version 1.2020 |
1.00 |
12/10/2019 - 12:00am to 12/10/2020 - 12:00am |
|
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2020 |
1.00 |
10/10/2019 - 12:00am to 10/10/2020 - 12:00am |
|
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 1.2020 |
1.00 |
03/10/2020 - 12:00am to 03/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Kidney Cancer, Version 2.2020 |
1.00 |
11/10/2019 - 12:00am to 11/10/2020 - 12:00am |
|
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020 |
1.00 |
01/10/2020 - 12:00am to 01/10/2021 - 12:00am |
|
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019 |
1.00 |
09/10/2019 - 12:00am to 09/10/2020 - 12:00am |
|
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 |
1.00 |
04/10/2020 - 12:00am to 04/10/2021 - 12:00am |
Facebook
Twitter
LinkedIn
Forward